Characterising asthma exacerbations in the CAPTAIN trial

L. Lee (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Kerwin (Medford, OR, United States of America), H. Kerstjens (Groningen, Netherlands), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), G. Peachey (Stockley Park West, Uxbridge, Middlesex, United Kingdom), N. Sule (Collegeville, PA, United States of America), N. Barnes (Brentford, Middlesex and London, United Kingdom), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), L. Boulet (Quebec, QC, Canada), N. Hanania (Houston, TX, United States of America), R. Nathan (Colorado Springs, CO, United States of America), S. Pascoe (Collegeville, PA, United States of America), I. Pavord (Oxford, United Kingdom), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom)

Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Session: Asthma and cough: clinical trials and pharmacological insights
Session type: E-poster session
Number: 2276
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Lee (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Kerwin (Medford, OR, United States of America), H. Kerstjens (Groningen, Netherlands), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), G. Peachey (Stockley Park West, Uxbridge, Middlesex, United Kingdom), N. Sule (Collegeville, PA, United States of America), N. Barnes (Brentford, Middlesex and London, United Kingdom), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), L. Boulet (Quebec, QC, Canada), N. Hanania (Houston, TX, United States of America), R. Nathan (Colorado Springs, CO, United States of America), S. Pascoe (Collegeville, PA, United States of America), I. Pavord (Oxford, United Kingdom), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom). Characterising asthma exacerbations in the CAPTAIN trial. 2276

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Montelukast reduces viral-induced asthma exacerbations: the PREVIA study
Source: Eur Respir J 2004; 24: Suppl. 48, 212s
Year: 2004

Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017


QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Methodologies for study of COPD exacerbations
Source: Annual Congress 2012 - ERS COPD exacerbation guidelines: methodologies and overview
Year: 2012

Evaluation of COPD exacerbations using the EXACT-U
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010


Effect of telehealthcare on exacerbations and hospital admissions in COPD: A randomised controlled trial
Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2015


Management of COPD exacerbations
Source: ERS Lung Science Conference 2019
Year: 2019


FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Lung function change and exacerbations in patients with COPD in the WISDOM study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Modelling exacerbations of COPD
Source: Annual Congress 2012 - Modelling respiratory infections: is it the future or the present?
Year: 2012


The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Prediction of future COPD exacerbations - DOSE index or a history of exacerbations?
Source: International Congress 2018 – Primary care management of COPD
Year: 2018

Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014


Tiotropium reduces COPD exacerbations: the MISTRAL study
Source: Eur Respir J 2004; 24: Suppl. 48, 513s
Year: 2004

Tele-monitoring intervention on COPD exacerbations
Source: International Congress 2016 – Novel approaches for pulmonary rehabilitation in chronic lung diseases
Year: 2016

Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Exacerbations of asthma and treatment
Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease
Year: 2018


Emergency visits for asthma: asthma exacerbations or poor asthma control?
Source: Eur Respir J 2004; 24: Suppl. 48, 598s
Year: 2004